|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
15
|
|
pubmed:dateCreated |
1985-9-6
|
|
pubmed:abstractText |
Cancers induced by physical or chemical carcinogens express tumor-specific antigens that are uniquely specific for any given tumor; therefore, there is a seemingly endless variety of these unique antigens. We have studied a UV-induced fibrosarcoma, designated 1591, to elucidate the obscure molecular nature and genetic origins of unique tumor-specific antigens. A monoclonal antibody raised against syngeneic 1591 tumor cells has unique tumor specificity. This tumor-specific monoclonal antibody precipitated from the tumor a 45-kDa molecule associated with a 12-kDa molecule having the pI of beta2-microglobulin. This and other evidence indicated that the 1591 tumor expresses a novel class I molecule. A 1591 variant selected for the absence of binding to the monoclonal antibody lacked the novel class I MHC molecule as well as reactivity with cytotoxic T lymphocytes specific for the 1591 tumor. Furthermore, tumor cells bearing the antigen are rejected while variants that have lost the antigen grow progressively. Fourteen of 14 host-selected progressor tumor variants lost reactivity with the monoclonal antibody and provided further evidence that this novel class I molecule is a transplantation antigen on the parental 1591 tumor required for immune rejection. The identification of a unique tumor-specific antigen as a novel class I major histocompatibility complex gene product allows us to search for the possible genetic mechanisms involved and to explore further the role such molecules play in tumor immunity and malignancy.
|
|
pubmed:grant |
|
|
pubmed:commentsCorrections |
http://linkedlifedata.com/resource/pubmed/commentcorrection/3860848-1085338,
http://linkedlifedata.com/resource/pubmed/commentcorrection/3860848-1091865,
http://linkedlifedata.com/resource/pubmed/commentcorrection/3860848-13502695,
http://linkedlifedata.com/resource/pubmed/commentcorrection/3860848-13756652,
http://linkedlifedata.com/resource/pubmed/commentcorrection/3860848-227958,
http://linkedlifedata.com/resource/pubmed/commentcorrection/3860848-288078,
http://linkedlifedata.com/resource/pubmed/commentcorrection/3860848-290545,
http://linkedlifedata.com/resource/pubmed/commentcorrection/3860848-373122,
http://linkedlifedata.com/resource/pubmed/commentcorrection/3860848-398326,
http://linkedlifedata.com/resource/pubmed/commentcorrection/3860848-4121493,
http://linkedlifedata.com/resource/pubmed/commentcorrection/3860848-4552543,
http://linkedlifedata.com/resource/pubmed/commentcorrection/3860848-5461774,
http://linkedlifedata.com/resource/pubmed/commentcorrection/3860848-6184620,
http://linkedlifedata.com/resource/pubmed/commentcorrection/3860848-6185615,
http://linkedlifedata.com/resource/pubmed/commentcorrection/3860848-6200978,
http://linkedlifedata.com/resource/pubmed/commentcorrection/3860848-6280871,
http://linkedlifedata.com/resource/pubmed/commentcorrection/3860848-6363595,
http://linkedlifedata.com/resource/pubmed/commentcorrection/3860848-6456650,
http://linkedlifedata.com/resource/pubmed/commentcorrection/3860848-6602947,
http://linkedlifedata.com/resource/pubmed/commentcorrection/3860848-6609361,
http://linkedlifedata.com/resource/pubmed/commentcorrection/3860848-6847892,
http://linkedlifedata.com/resource/pubmed/commentcorrection/3860848-6895187,
http://linkedlifedata.com/resource/pubmed/commentcorrection/3860848-6966311,
http://linkedlifedata.com/resource/pubmed/commentcorrection/3860848-6966405,
http://linkedlifedata.com/resource/pubmed/commentcorrection/3860848-6977009,
http://linkedlifedata.com/resource/pubmed/commentcorrection/3860848-7058331,
http://linkedlifedata.com/resource/pubmed/commentcorrection/3860848-7153707,
http://linkedlifedata.com/resource/pubmed/commentcorrection/3860848-7276830,
http://linkedlifedata.com/resource/pubmed/commentcorrection/3860848-959840
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Aug
|
|
pubmed:issn |
0027-8424
|
|
pubmed:author |
|
|
pubmed:issnType |
Print
|
|
pubmed:volume |
82
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
5140-4
|
|
pubmed:dateRevised |
2009-11-18
|
|
pubmed:meshHeading |
pubmed-meshheading:3860848-Animals,
pubmed-meshheading:3860848-Antibodies, Monoclonal,
pubmed-meshheading:3860848-Antibodies, Neoplasm,
pubmed-meshheading:3860848-Antigens, Neoplasm,
pubmed-meshheading:3860848-Cross Reactions,
pubmed-meshheading:3860848-H-2 Antigens,
pubmed-meshheading:3860848-Major Histocompatibility Complex,
pubmed-meshheading:3860848-Mice,
pubmed-meshheading:3860848-Neoplasms, Experimental
|
|
pubmed:year |
1985
|
|
pubmed:articleTitle |
Identification of a unique tumor-specific antigen as a novel class I major histocompatibility molecule.
|
|
pubmed:publicationType |
Journal Article,
Research Support, U.S. Gov't, P.H.S.
|
